Project description
Confronting non-small cell lung cancer challenges with innovative therapies
Non-small cell lung cancer (NSCLC) destroys lives worldwide, with traditional treatments targeting life extension and overall survival measured in months. Surgery, chemotherapy, radiotherapy, and even newer gene therapies and immunotherapies present challenges in terms of side effects and patient response, especially for those in advanced stages. With this in mind, Celtic Biotech in Ireland developed CB-24, a naturally derived receptor binding protein. Delivered as a user-friendly at-home monotherapy using infusion pumps, it boasts unprecedented efficacy, safety, and minimal side effects, challenging the status quo of NSCLC treatment. The EIC-funded CB24 project aims to validate its success, propelling it through Phase I clinical trials and towards regulatory approval as a game-changing cancer therapeutic.
Objective
Celtic Biotech Ireland has developed CB24(Crotoxin). A naturally derived receptor binding protein, delivered as monotherapy at home using infusion pumps, is hailed as a life changing treatment of Non-Small Cell Lung Cancer (NSCLC). Delivered intravenously, CB24 induces predictable and consistent apoptosis (cell death) and autophagy (degradation) in human lung carcinoma cells. CB24 outclass the competitive NSCLC treatment solutions (surgery, chemotherapy, and radiotherapy) through its efficacy, safety, minimal side-effects, easy to use home based treatment and suitability for all patients including those at stage 3 & 4.
Celtic have already proven the efficacy of CB24 through pre-clinical and FIH clinical trials.
Through the proposed 24months EIC project, the company aims to undertake Phase I Part 3 clinical trials involving 24 patients with the ultimate goal of garnering the regulatory approvals (EMA, FDA) to market the drug as a verified cancer therapeutic.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine oncology lung cancer
- natural sciences biological sciences biochemistry biomolecules proteins
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2023-ACCELERATOR-01
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
D02 NX53 DUBLIN
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.